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a b s t r a c t
Background: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a
catch-up campaign for children aged <5 years in Kilifi County. In a post-vaccination surveillance study
based in Kilifi, there was a substantial decline in invasive pneumococcal disease (IPD). However, given
the continued circulation of the vaccine serotypes it is possible that vaccine-serotype disease may
re-emerge once the effects of the catch-up campaign wear off.
Methods: We developed a compartmental, age-structured dynamic model of pneumococcal carriage and
invasive disease for three serotype groups: the 10-valent vaccine serotypes and two groups of non-
vaccine serotypes based on their susceptibility to mutual competition. The model was calibrated to
age- and serotype-specific data on carriage and IPD in the pre-vaccination era and used to predict carriage
prevalence and IPD up to ten years post-vaccination in Kilifi. The model was validated against the
observed carriage prevalence after vaccine introduction.
Results: The model predicts a sustained reduction in vaccine-type pneumococcal carriage prevalence
from 33% to 8% in infants and from 30% to 8% in 1–5 year olds over the 10-year period following vaccine
introduction. The incidence of IPD is predicted to decline across all age groups resulting in an overall
reduction of 56% in the population, corresponding to 10.4 cases per 100,000 per year. The vaccine-type
IPD incidence is estimated to decline by 83% while non-vaccine-type IPD incidence is predicted to
increase by 52%. The model’s predictions of carriage prevalence agrees well with the observed data in
the first five years post-vaccination.
Conclusion: We predict a sustained and substantial decline in IPD through PCV vaccination and that the
current regimen is insufficient to fully eliminate vaccine-serotype circulation in the model. We show that
the observed impact is likely to be sustained despite waning effects of the catch-up campaign.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
Reduction in nasopharyngeal carriage of vaccine-type pneumo-
cocci has been documented after vaccination with pneumococcal
conjugate vaccines (PCVs) [1–3]. Moreover, by reducing pneumo-
coccal acquisition, PCVs reduce pneumococcal transmission in
the community offering indirect protection to the unvaccinated
[4]. However, non-vaccine-type pneumococci rapidly colonise this
vacated ecological niche, which can result in serotype replacement
carriage [5] and replacement disease reducing the overall impact of
PCVs [6]. With support from Gavi, The Vaccine Alliance, African
countries have been introducing PCVs since 2009. Kenya intro-
duced a 10-valent PCV (PCV10) targeting serotypes 1, 4, 5, 6B, 7F,
9V, 14, 18C, 19F and 23F in 2011. In Kilifi, a coastal area with
enhanced surveillance for invasive pneumococcal disease (IPD)
and carriage prevalence, the introduction was supplemented by a
catch-up campaign in children <5 years old. At the same time
http://dx.doi.org/10.1016/j.vaccine.2017.07.019
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annual carriage prevalence surveys have been conducted in the Kil-
ifi Health and Demographic Surveillance System (KHDSS) popula-
tion since 2009 [5].
Within a few months post-vaccination vaccine-type pneumo-
coccal carriage and disease had dropped substantially in all age
groups. However, vaccine serotypes (VTs) continue to circulate in
the community [7,5]. This raises the concern that, after the popu-
lation effects of the catch-up campaign have worn off, vaccine-
type pneumococcal disease will re-emerge.
We developed a dynamic compartmental model parameterized
with detailed data from the KHDSS population [8] to describe the
pre-vaccination pneumococcal epidemiology and predict the
long-term impact of PCV10 in Kilifi. We use post-vaccination data
on carriage and disease over the past five years for validation of the
model predictions.
2. Methods
2.1. Data
Kilifi County Hospital (KCH) is the main referral hospital in
KHDSS. At KCH, morbidity events linked with the population regis-
ter have been used to define the incidence of hospital presentation
with infectious diseases, including IPD [8,9]. Datasets on pneumo-
coccal carriage, IPD and contact patterns in KHDSS are described in
detail elsewhere [5,10,11]. Here we briefly describe them as used
in the current analysis.
2.1.1. Nasopharyngeal pneumococcal carriage surveys
Two cross-sectional surveys of pneumococcal carriage were
done pre-vaccination. Nasopharyngeal swabs were collected and
pneumococcal serotype-specific carriage ascertained [5] to obtain
the pre-vaccination age-specific prevalence and serotype distribu-
tion of carriage. The two datasets were combined since there were
no significant differences between them in the carriage prevalence
or serotype distribution (Appendix chapter 1).
The non-vaccine serotypes (NVTs) were classified as weak or
strong based on their susceptibility to competition and carriage
incidence, as estimated in a prior field study within KHDSS [12].
Strong NVTs (23B, 11A, 15A, 6A, 16F, 35B, 10A, 13, 23A 19A, 21;
ordered by increasing susceptibility to competition) were less sus-
ceptible to competition. Two NVTs (34, 15B/C) were classified as
strong for their higher carriage incidences compared to many of
the ones chosen on the basis of susceptibility. The remaining NVTs
were classified as weak (Appendix chapter 2).
2.1.2. Prospective diary survey
Selected residents from KHDSS filled in a diary on the ages of all
persons they physically contacted on one randomly assigned
weekday [10]. For children, the diary was completed by their guar-
dians. This information defined a social mixing matrix of contact
frequencies between age groups.
2.2. Carriage model structure
We developed a compartmental, age-structured dynamic model
with 14 pneumococcal carriage states (Fig. 1). The model has a Sus
ceptible-Infected-Susceptible (SIS) structure for three serotype
groups: the PCV10 serotypes, strong NVT and weak NVT.
At any point in time, an unvaccinated individual can be suscep-
tible (non-carrying) in state S; carry a VT, V; carry a weak NVT, Nw;
carry a strong NVT, Ns; carry simultaneously a weak and strong
NVT, Nsw; carry simultaneously a VT and weak NVT, Bw; or carry
simultaneously a VT and a strong NVT, Bs. Once vaccinated, the
individual moves to one of the corresponding states (SðvÞ, V ðvÞ,
NðvÞw , N
ðvÞ
s , N
ðvÞ
sw , B
ðvÞ
w , B
ðvÞ
s ). The equations of inter-state transitions
are presented in Appendix chapter 3.
Fig. 1. Model structure flow diagram. The epidemiological states include individuals that are susceptible (non-carrying), S; carry a vaccine serotype, V; carry a weak non-
vaccine serotype, Nw; carry a strong non-vaccine serotype, Ns; carry simultaneously a weak and a strong non-vaccine serotype, Nsw; carry simultaneously a vaccine serotype
and a weak non-vaccine serotype, Bw; or carry simultaneously a vaccine serotype and a strong non-vaccine serotype, Bs (see text). Once vaccinated, the individual moves to
one of the corresponding states, ðSðvÞ;V ðvÞ;NðvÞw ;NðvÞs ;BðvÞw andBðvÞs Þ. The acquisition rates from the single to multiple serotype carriage states are reduced by competition
parameters denoted by c with two subscripts; the first denoting the serotype group (v ; sandw, for VT, strong NVT and weak NVT respectively) of the resident serotypes and
the second denoting the age-group. The competition parameters have two sets of values, one for age group <6 and another for age group 6 years (see text). The age-group
specific VT, weak NVT and strong NVT clearance rates are denoted by rVi; rNwi and rNsi , respectively. In addition to the transitions between the 14 epidemiological states as
shown in the figure, individuals die from any states at age-specific death rates and new individuals are born into the completely susceptible state.
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2.3. Parameterisation
2.3.1. Population structure
The model population is stratified into six age groups (<1, 1–5,
6–14, 15–20, 21–49 andP50 years) corresponding to those in the
diary survey and reflecting the age structure in KHDSS as of 1st
January 2010. Individuals in the model are born completely sus-
ceptible to carriage according to prevailing birth rates and die
according to age-specific mortality rates from KHDSS (Table 1).
2.3.2. Acquisition of carriage
A susceptible unvaccinated individual in age group i becomes
colonised with VTs, strong NVTs or weak NVTs at age-group-
specific time-dependent rates (forces of infection) denoted by
kViðtÞ, kNsiðtÞ and kNwiðtÞ, respectively. The forces of infection were
expressed as functions of the social mixing matrix and age-group
specific factors (qi) that scale the rate of social contacts into infec-
tious contacts (Appendix chapter 3). Due to competition between
serotypes in colonising the nasopharynx, the acquisition rate of a
secondary serotype is lower than the acquisition rate of that sero-
type in a completely susceptible individual. Three competition
parameters, cv0, cw0 and cs0, represent the fraction by which acqui-
sition rates of secondary serotypes are reduced in <6 year olds
infected with VTs, weak NVTs and strong NVTs, respectively. Two
competition parameters, cvw ¼ cv ¼ cw and cs, were used for indi-
viduals aged P6 years infected with VTs/weak NVTs and strong
NVTs, respectively.
2.3.3. Clearance of carriage
The immune clearance rates of carriage (Appendix chapter 4)
depend on the serotype group and age (<1, 1–5 and >5 years)
and were obtained from a prior study in Kenyan children [12].
2.3.4. Disease
For each serotype group and age group, case-to-carrier ratios
were calculated as ratios of the observed IPD incidence at KCH
[11] to the respective model-predicted pre-vaccination carriage
incidence. The case-to-carrier ratios were assumed to remain
unchanged post-vaccination and were multiplied with the pre-
dicted carriage incidence to predict post-vaccination IPD incidence.
2.3.5. Vaccination
In Kenya, children receive PCV10 at age 6, 10 and 14 weeks. In
the model, g=80% of all newborns are considered vaccinated at
age 18 weeks, one month after the third dose of the 3-dose series
(Table 1). A catch-up programme is simulated by vaccinating 65%
of children younger than 5 years at the onset of the vaccination
programme. Upon vaccination, an individual moves to the corre-
sponding state in the vaccine-protected compartment based on
his/her prevailing carriage status.
The vaccine efficacy against carriage is modelled as a 50% reduc-
tion (e ¼ 0:50) in the acquisition rate of VTs in a vaccinated indi-
vidual relative to an unvaccinated individual (Table 1). The
vaccine efficacy against carriage progression to disease (VEprog)
was calculated as a function of e and the vaccine efficacy against
IPD (VEIPD = 85%) as:
VEprog ¼ 1 1 VEIPD1 e ¼ 70%:
We assumed that a proportion u = 0.12 of the vaccinated popu-
lation loses their protection every year. This corresponds to an
average duration of protection for an individual of just over 8 years
(Table 1).
2.3.6. Implementation and model calibration
In the first stage, the stationary solution of the transmission
model was fitted to the age-stratified pre-vaccination carriage
prevalence and serotype distribution (Appendix chapter 1). Using
a multinomial likelihood function and uninformative priors in a
Bayesian framework, the five competition parameters (cvw, cv0, cs,
cs0 and cw0) and six scaling/infectivity parameters
ðq1; q2; q3; q4; q5; q6Þ were estimated (Appendix chapter 5). In each
iteration, bootstrapping the social contact data and reconstructing
the mixing matrix incorporated uncertainty in the social contact
rates. A stationary population with equal birth and mortality rates
was assumed.
In the second stage, the posterior samples of model parameters
obtained in the first stage were applied in a prediction model. Pro-
jections were made assuming a constant population. To measure
how fast the effect of the catch-up campaign wanes, we calculated
the additional cases of IPD the campaign prevents in the first
10 years and estimated the time required to achieve 90% of that
effect. Simulations were performed in R [13].
2.4. Sensitivity analysis
The sensitivity of the predicted IPD incidence averted, i.e., the
difference in the overall incidence of IPD before and at 10 years
post-vaccination, was assessed with respect to uncertainties in
the assumed levels of: (i) vaccine efficacy against carriage acquisi-
tion; (ii) vaccine efficacy against IPD; (iii) the waning rate of
vaccine-induced protection against carriage; (iv) vaccine coverage.
We performed additional simulations under a growing popula-
tion using birth and death rates corresponding to the local demo-
Table 1
Parameters of the dynamic transmission model and the sources of information. The
parameters are classified as those estimated (calibrated) in the context of the model
and those derived from external sources.
Parameter/input Estimate/value
(intervala)
Source
Calibrated
Competition parameters cs0 = 0.44 (0.13, 0.82)
cw0 = 0.59 (0.19, 0.96)
cv0 = 0.39 (0.15, 0.71)
cs = 0.11 (0.004, 0.49)
cvw ¼ cv ¼ cw = 0.77
(0.30, 0.99)
Estimated
Probability of infection per 100
contacts
q1 = 0.13 (0.07, 0.25)
q2 = 0.40 (0.30, 0.55)
q3 = 0.32 (0.24, 0.43)
q4 = 0.07 (0.04, 0.13)
q5 = 0.16 (0.11, 0.23)
q6 = 0.06 (0.04, 0.09)
Estimated
Case-to-carrier ratiosb Appendix chapter 7 [11]
From external sources
Clearance rates Appendix chapter 3 [12]
Birth rate 32.0 per 1000/year [8]
Age-specific mortality Appendix chapter 5 [8]
Contact rates [10]
Vaccine efficacy against carriage
acquisition (e)
50% (40–60) [3,25–27]
Vaccine efficacy against IPD 85% (80–90) [34]
Waning rate of protection against
carriage (u)
0.12 per year (0.09–0.20) [35]
Routine vaccination coverage (g) 80% (70–90) [9,11]
Catch-up coverage 65% (60–70) [9,11]
a The intervals indicated for the estimated parameters are 95% credible intervals.
The intervals indicated for the rest of the parameters are the ranges within which
they were sampled in the model to account for their uncertainty and assess the
model’s sensitivity.
b IPD incidence from Kilifi district hospital in KHDSS is divided by the carriage
incidence from the model to obtain case-to-carrier ratios (Appendix chapter 7).
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graphics [8]. The probabilities of contact per person per day were
recalculated for each time step according to the current population
(Appendix chapter 6).
2.5. Model validation
We visually assessed proximity of the base-case predictions of
the age-group specific carriage of VTs and NVTs to the correspond-
ing observed values over a five-year period post-vaccination
(2011–2015).
3. Results
3.1. Model fit to pre-vaccination epidemiology
There was a good agreement between the observed age-group
and serotype-group specific pre-vaccination carriage prevalence
and their posterior estimates (Fig. 2). Within each age group, the
95% credible intervals agreed with the data. Nonetheless, the dif-
ferences in the posterior mean estimates of the proportions of car-
riers of VTs and NVTs among pneumococcal carriers were in most
instances larger than observed in individuals 6 years old, com-
pared to the differences in individuals <6 years old.
3.2. Competition parameters
The probability of infection per contact was higher among 1–5
and 6–14 year olds as compared to other age groups (Table 1).
An individual <6 years carrying a vaccine-serotype had a 61%
(95% credible interval, CrI, 29–85%) protection against acquiring
NVTs, relative to an uninfected individual of the same age group.
In older age groups, the corresponding level of protection was
23% (95% CrI 1–70%).
3.3. Model projections on pneumococcal carriage
Under the base-case model, the overall prevalence of pneumo-
coccal carriage was estimated to remain essentially at its pre-
vaccination level, with only a slight reduction from 44% to 41%
within 10 years post-vaccination. The prevalence of VTs in the
overall population was estimated to reduce from 16% to 4%, with
a simultaneous increase in the prevalence of NVTs from 28% to
36%.
The prevalence of VTs was predicted to reduce in all age groups.
In the older, mostly unvaccinated population, the reduction was
estimated to be about two thirds of the pre-vaccination level
(Table 2), suggesting a benefit of herd immunity. Changes in the
prevalence of VTs and NVTs occur within the first 4–5 years post-
vaccination and little change was predicted thereafter (Fig. 3).
3.4. Model projections on IPD
The incidence of IPD from VTs was projected to decline in all age
groups. The changes in IPD and carriage were linked and over 50%
reduction in IPD occurs within the first 4–5 years after PCV intro-
duction. The overall reduction in the incidence of IPD ten years
post-vaccination is predicted to be 56% (Table 3). The overall
reduction in the incidence of IPD from year 5 to 10 was 7% (95%
predictive interval: 0.4% to 14%). As a result of waning direct
Fig. 2. Model fit. Observed prevalence (red points) of pneumococcal carriage across age groups (top-left panel) and the proportion of carriers of VT (top-right panel), strong
NVT (bottom-left panel) and weak NVT (bottom-right panel) among pneumococcal carriers prior to vaccine introduction. The black points show the corresponding estimated
values of the prevalence/proportion, based on data given in Appendix chapter 1. The capped bars represent the 95% credible intervals. The dotted lines in the top-left panel
(and the points they pass through) are the observed (red) and the predicted (black) proportions of double carriers among <1 and 1–5 year olds. For these two age groups, the
top-right, bottom-left and bottom-right panels present the proportions of single carriers of the respective types (VT, strong NVT, weak NVT) among all carriers in the age
group. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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effects of the catch-up campaign and increasing herd-effects of
routine immunisation with time, we estimated that the incremen-
tal benefit of a catch-up over routine vaccination alone would be
negligible from year 7 after introduction of PCV10.
3.5. Sensitivity analyses
Among the variables included in the sensitivity analysis, the
duration of protection had the largest effect on the predicted IPD
incidence averted in year 10, followed by the vaccine efficacy
against carriage. The vaccine efficacy against IPD had the least
influence (Fig. S1).
Assuming a growing population, the overall prevalence of car-
riage was projected to decline to a somewhat lower level of 35%
(95% prediction interval 30–40%) ten years post-vaccination
(Appendix chapter 7).
3.6. Model validation
The point predictions and corresponding 95% prediction inter-
vals (PI) of carriage prevalence cover most of the observed values,
showing good predictive ability (Fig. S2). Among <1 and 1–5 year
olds the model predicted much lower carriage prevalence of NVTs
in year 2015 (49% vs. 70% observed and 38% vs. 52% observed,
respectively).
4. Discussion
We used a model calibrated with local data to predict the
incidence of pneumococcal carriage and IPD in Kilifi, Kenya, over
a 10-year period post-vaccination to assess whether additional
measures have to be considered to prevent a resurgence of
vaccine-type pneumococci once the impact of the catch-up
campaign wanes. We validated the model against immediate
post-vaccination epidemiological data, a unique exercise in
pneumococcal carriage models, and found that such resurgence
is unlikely if the routine immunisation programme continues.
Most PCV introductions in African countries have occurred since
year 2011. Therefore, only a few years of observation are available
to assess impact. A meta-analysis of four randomized trials in
African children aged 9–24 months showed that carriage of VTs
decreased with vaccination but the overall carriage remained the
same [14]. In the United Kingdom, the overall prevalence of pneu-
mococcal carriage was stable four years post-vaccination [15]. In
our model predictions, the overall carriage prevalence remains
essentially unchanged due to serotype replacement in carriage.
Replacement carriage was most prominent in <6 year olds because
the pre-vaccination proportion of VTs among pneumococcal
carriers was highest in young children (Appendix chapter 1). We
predict that elimination of VTs in this community is unlikely. In
high-income countries that have almost eliminated circulation of
VTs, a reduced-dose schedule has been considered to improve
the cost-effectiveness of the programme [16]. The World Health
Organization (WHO) also recently convened a working group to
review the policy recommendations for the optimal use of PCVs
in low- and middle-income countries, which includes discussion
of reduced dose schedules [17]. Theoretically, where herd protec-
tion has been established, it may be possible to sustain it using,
for example, a single dose in infancy and a booster dose in the sec-
ond year of life. In the Kenyan setting, however, where vaccine-
type pneumococci continue to circulate several years post intro-
duction of PCV with a catch-up campaign, it would be difficult to
argue that disease prevention among infants is currently guaran-
teed by herd protection.
In the model presented, the incidence of IPD is predicted to
decline across all age groups. The non-vaccine-type IPD incidence
is expected to increase by 52%, which translates to an increase in
the annual incidence of 1.9 per 100,000, suggesting little replace-
ment disease relative to the reduction in the annual overall
vaccine-type IPD incidence of 12.3 per 100,000. This is explained
by the lower average case-to-carrier ratios (i.e., lower invasive-
ness) of the replacing non-vaccine serotypes (Appendix chapter 8).
South Africa and The Gambia introduced PCV7 in 2009 and
replaced it with PCV13 in 2011 [18,19]. The reduction in vaccine-
type and overall IPD reported in these countries are similar to
the predictions our model produces for Kilifi, Kenya, over the first
few years post-vaccination. This, however, does not validate the
model because of differences across the settings. The vaccination
coverage in Kenya is likely to differ from coverage in The Gambia
and South Africa, and Kenya introduced PCV10. We thus validated
our model predictions against observed carriage prevalence and
IPD incidence in Kilifi. The model predictions were generally con-
sistent with the observed data (Fig. S2). The model, however,
underestimated prevalence of carriage of NVTs in <6 year olds in
2014–15. Relaxing the assumption of a constant population size
only made minimal difference to the goodness of fit (Fig. S3).
Pneumococcal serotypes are heterogeneous in transmissibility
and mutual competition [12,20]. By splitting the NVTs into two
groups and allowing unequal mutual competition between these
groups, our model accounts for some of this heterogeneity. We
did not split VTs because we aimed to reproduce serotype replace-
ment with as small a number of parameters as possible, by limiting
the number of compartments. Splitting NVTs was preferred
because the group has a larger number of serotypes and hence
more heterogeneity. The model projected differing magnitudes of
change in the prevalence of the strong and weak NVTs. Given the
different case-to-carrier ratios of the two groups of NVTs
Table 2
The prevalence of nasopharyngeal carriage of pneumococci pre- and 10 years post-vaccination. The table presents the posterior predictive mean values with the 95% posterior
predictive intervals.
Age group
(years)
Pre-vaccination 10 years post-vaccination
Carriage prevalence VTa Strong NVTb Weak NVT Carriage prevalence VT Strong NVT Weak NVT
<1 80.8 (67.8–90.1) 32.6 (25.1–40.5) 37.5 (30.6–45.8) 9.9 (7.1–13.2) 75.7 (61.4–87.2) 8.3 (1.6–18.2) 50.9 (40.9–62.6) 15.2 (10.5–22.2)
1–5 72.5 (65.2–78.5) 29.5 (23.9–35.2) 29.7 (24.6–35.2) 13.1 (9.6–17.0) 67.2 (58.9–74.6) 8.0 (1.5–16.9) 39.2 (32.2–48.5) 19.3 (14.1–25.5)
6–14 54.0 (43.1–64.8) 17.0 (13.9–21.2) 26.8 (18.9–35.0) 9.9 (7.4–13.5) 49.7 (38.6–61.0) 4.4 (0.9–9.6) 32.0 (23.6–41.2) 12.8 (9.5–17.1)
15–20 27.9 (17.0–41.7) 9.1 (5.7–13.9) 13.4 (7.6–20.7) 5.3 (3.1–8.6) 25.3 (15.6–38.0) 2.5 (0.5–6.0) 15.8 (9.5–24.3) 6.8 (4.1–10.8)
21–49 25.5 (17.0–35.5) 8.6 (5.8–12.1) 12.0 (7.6–17.5) 4.8 (3.0–7.2) 23.2 (15.2–33.0) 2.5 (0.5–5.6) 14.2 (9.2–20.9) 6.2 (3.9–9.3)
50+ 21.0 (14.0–30.0) 7.1 (4.7–10.1) 9.8 (6.2–14.6) 4.0 (2.6–6.0) 19.1 (12.7–27.3) 2.0 (0.4–4.5) 11.7 (7.6–17.2) 5.2 (3.3–7.9)
Overall 44.4 (40.2–48.9) 15.9 (13.3–18.7) 20.4 (16.8–24.2) 8.0 (6.1–10.2) 40.8 (36.0–46.0) 4.3 (0.8–9.1) 25.4 (21.2–30.0) 10.9 (8.4–13.8)
a Vaccine serotypes.
b Non-vaccine serotypes.
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(Appendix chapter 8), the projected non-vaccine-type IPD inci-
dence is different from what would have been predicted using a
single group of NVTs. Nonetheless, grouping serotypes can create
some ‘super types’ that might have different characteristics, e.g.
higher acquisition rate of the VTs group compared to the individual
serotypes in the group. This might lead to conservative vaccine
effectiveness estimates. Grouping of serotypes may also result in
the estimated acquisition rate of NVTs being lower than that of
individual serotypes in the group. This would lead to an underesti-
mation of the indirect impact of vaccination on NVTs - lower than
the observed predicted prevalence of NVTs.
To limit the number of estimated parameters, age dependency
in competition was considered using two age classes (<6 and
P6 years). Some discrepancies between the fitted and observed
age-specific serotype distributions were present. The proportion
of carriers of VTs was overestimated among carriers aged
15 years (Fig. 2); the susceptibility to competition of VTs against
NVTs is likely biased downwards in adults, thus underestimating
the reduction in prevalence of VTs. With our current specification,
the estimates of competition parameters in age group 6 years lar-
gely depends on data from the age groups 6–14 years. A model
including more groups of VTs and NVTs or individual serotypes
Fig. 3. Model projections on carriage prevalence over 10 years by age group. Projected cumulative prevalence of pneumococcal carriage of VT (red), strong NVT (blue) and
weak NVT (lime green) by age group over time since vaccine introduction. For each age group, the dotted lines show the 95% predictive intervals for the overall prevalence of
pneumococcal carriage. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
4566 J. Ojal et al. / Vaccine 35 (2017) 4561–4568
[21–23] would allow for even more heterogeneity. However, the
estimation of competition parameters from available carriage data
would become increasingly difficult in a highly compartmentalized
model.
We estimated case-to-carrier ratios using hospital-based data
on IPD incidence in KHDSS [8]. The access to care for IPD is
unknown in KHDSS, but meningitis incidence is underestimated
by over 30% by hospital-based surveillance [24]. Since IPD and
meningitis are severe syndromes, the underestimation of IPD inci-
dence could be similar implying case-to-carrier ratios are likely
underestimated. Nonetheless, since the ratios estimated pre-
vaccination are applied post-vaccination, the predicted reduction
in IPD is not affected.
We excluded partial protection from first and second doses. Our
estimates of the vaccine impact may thus be conservative if the
vaccines’ efficacy is substantial after fewer than three doses. We
treated vaccine efficacy against carriage and its waning as equal
for routine and catch-up vaccination. A Kenyan trial estimated vac-
cine efficacy against carriage of 40% among children aged 1–
4 years [3], lower than the 50% for infant vaccination [25–27].
The duration of protection of catch-up vaccination is not docu-
mented yet. One dose of PCV administered outside of infancy
may have a more enduring effect than 3 routine infant doses. If
so, our similar treatment of the duration of immunity means there
is no inflection on the carriage prevalence of VTs as the cohort of
highly immune <5 year olds who received a catch-up dose is
replaced by a new birth cohort of less immune children over time.
We assumed children are born completely susceptible to acqui-
sition of pneumococcus ignoring the influence of maternal anti-
bodies. Newborns in a Kenyan study had a very high rate of first
acquisition [20]. Early acquisition has also been reported in other
African settings [28–30]. In Netherlands and Papua New Guinea a
protective effect of maternal IgG antibodies against colonisation
in infancy was not observed [31,32]. Based on high early acquisi-
tion rates and insufficient evidence of protection from maternal
antibodies in some studies, this assumption is plausible.
A significant reduction in IPD caused by vaccine-related sero-
types 6A and 19A IPD has been observed in some PCV10-using set-
tings [33]. However, surveillance in Kilifi recorded no change in
carriage of serotype 6A and increased carriage of serotype 19A
after vaccine introduction [7]. We have not observed a change in
IPD caused by these serotypes. We therefore did not account for
6A and 19A as vaccine serotypes.
In conclusion, we predict a substantial and sustainable decline
in the carriage prevalence of VTs among vaccinated and unvacci-
nated individuals and consequently a reduction of about 56% in
overall IPD incidence ten years post-vaccination. While we show
that the current schedule is sufficient to limit vaccine-type pneu-
mococcal carriage to current levels, it is unlikely to achieve elimi-
nation of VTs. Strategies that heavily rely on protection from the
herd, including a reduced dose schedule, will need additional
efforts to stop circulation of VTs before their implementation.
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